Oncology has changed dramatically over recent years - a deeper understanding of tumor drivers, cancer biology and immunology has led to a plethora of new treatment approaches, including targeted molecules and cancer immunotherapies. State of the art diagnostics predict efficacy of treatments across cancer types and independent of "standard" tumor classifications by tissue of origin. In the future, the confluence of cutting-edge medicines, comprehensive diagnostics and genomic sequencing, and the application of new technologies and data sources (including real-world data) will lead to an even more personalized paradigm. These developments pose both opportunities and challenges from a pharmaceutical and biotechnology perspective.
Dr. Dietmar Berger will speak about Genentech's approach to this changing oncology landscape, including development of novel targeted therapies, integration of diagnostic platforms, and personalized cancer immunotherapy. Novel trial designs and rapid application of new biomarker insights have led to accelerated pathways for clinical testing and regulatory submissions. Dr. Berger will also discuss the mechanism of action of selected immunotherapy and small molecule products in the clinic and the progress of selected clinical candidates in solid tumors and hematology.
Dietmar Berger is Senior Vice President and Global Head, Product Development, Clinical Hematology and Oncology at Roche/Genentech. In this role, Dr. Berger leads the medical strategy for the company's global clinical development portfolio for cancer medicines. Dr. Berger was formerly Vice President of Global Clinical Development for Roche/Genentech's HER2 breast cancer franchise and was instrumental in the development and marketing approvals of two breast cancer medicines across three new indications.
Dr. Berger has more than 20 years of experience in oncology research and development, including as Head of the Clinical Research Center at the University Medical Hospital, Freiburg, Germany. He has held leadership positions at several global pharmaceutical companies and also received the Cancer Award of the German Cancer Society for his research on angiogenesis. Dr. Berger has authored more than 40 scientific publications and five books.